Menu
Search
|

Menu

Close
X

Cytosorbents Corp CTSO.OQ (NASDAQ Stock Exchange Capital Market)

7.85 USD
-- (--)
As of Feb 22
chart
Previous Close 7.85
Open --
Volume --
3m Avg Volume 18,959
Today’s High --
Today’s Low --
52 Week High 8.10
52 Week Low 3.35
Shares Outstanding (mil) 28.13
Market Capitalization (mil) 173.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
7
FY16
10
FY15
5
EPS (USD)
FY17
-0.094
FY16
-0.472
FY15
-0.335
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
14.21
5.77
Price to Book (MRQ)
vs sector
21.86
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
125.58
16.52
LT Debt to Equity (MRQ)
vs sector
100.31
12.22
Return on Investment (TTM)
vs sector
-77.87
14.43
Return on Equity (TTM)
vs sector
-162.40
16.13

EXECUTIVE LEADERSHIP

Al Kraus
Chairman of the Board, Since 2008
Salary: $216,351.00
Bonus: --
Phillip Chan
President, Chief Executive Officer, Director, Since 2009
Salary: $245,386.00
Bonus: $50,000.00
Kathleen Bloch
Chief Financial Officer, Since 2013
Salary: $200,000.00
Bonus: $55,000.00
Vincent Capponi
Chief Operating Officer, Since 2005
Salary: $239,445.00
Bonus: $40,000.00
Eric Mortensen
Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

7 Deerpark Dr Ste K
MONMOUTH JUNCTION   NJ   08852-1921

Phone: +1973.3298885

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

SPONSORED STORIES